drugset / Trial / NCT00200447

An Open-Label Feasibility/Pilot Study With [123I]-IBZM SPECT (DOPA-SYN)

NCT00200447 ↗

Phase 2 Completed 3 enrolled Molecular NeuroImaging
RandomizedCrossoverOpen-labelTreatment

Summary

This study conducted to more fully evaluate the way that carbidopa/levodopa and entacapone may work in the brain. This research study uses \[123I\]-IBZM and dynamic SPECT imaging to determine the amount and the duration of dopamine release from specific regions in the brain after treatment with either the combination of carbidopa/levodopa or the combination of carbidopa/levodopa/entacapone.

Timeline

Start
2004-03
Primary completion
2004-09
Completion
2004-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Carbidopa Unknown 37.5 mg Oral
Subject Carbidopa Unknown 50 mg Oral
Subject Entacapone Small molecule 200 mg Oral
Subject L-dopa Peptide 150 mg Oral
Subject L-dopa Peptide 250 mg Oral

Indications